Effective weight-loss programs have proven hard to implement at large scale, and many health-care systems are not prepared to intervene in diabetes early, according to researchers at medical journal Lancet.

Drugmakers have been rushing to develop obesity pills (to rival obesity shots like Wegovy), angling for a piece of a market that some estimate will one day be worth as much as $100 billion.